. 2016 Jun 15:781:83-91.
doi: 10.1016/j.ejphar.2016.04.004. Epub 2016 Apr 6.
Tamara Perleta Stambolija 1 , Jadranka Katancic Holjevac 1 , Tamara Murselovic 1 , Jelena Radonic 1 , Viktor Duzel 1 , Bozidar Duplancic 1 , Sandra Uzun 1 , Gordana Zivanovic-Posilovic 1 , Danijela Kolenc 2 , Domagoj Drmic 1 , Zeljko Romic 1 , Sven Seiwerth 2 , Predrag Sikiric 3
Affiliations
PMID: 27060013 DOI: 10.1016/j.ejphar.2016.04.004
BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias
Vasilije Stambolija et al. Eur J Pharmacol. 2016.
Abstract
After the demonstration of its life-saving effect in severe hyperkalemia and the recovery of skeletal muscle after injury, pentadecapeptide BPC 157 has been shown to attenuate the local paralytic effect induced by succinylcholine, in addition to systemic muscle disability (and consequent muscle damage). Hyperkalemia, arrhythmias and a rise in serum enzyme values, were counteracted in rats. Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle). BPC 157 (10μg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances. BPC 157 completely eliminated hyperkalemia and arrhythmias, markedly attenuated or erradicated behavioral agitation, muscle twitches, motionless resting and completely eliminated post-succinylcholine hyperalgesia. BPC 157 immediately eliminated leg contractures and counteracted both edema and the decrease in muscle fibers in the diaphragm and injected/non-injected anterior tibial muscles. Therefore, the depolarizing neuromuscular blocker effects of succinylcholine were successfully antagonized.
Keywords: Arrhythmias; BPC 157; Hyperkalemia; Rats; Succinylcholine.
Copyright © 2016 Elsevier B.V. All rights reserved.
PubMed Disclaimer